probable CAA 患者中 Aβ PET 阳性的临床意义
该研究纳入 65 例符合改良 Boston 标准的 probable CAA 患者,评估 Aβ PET 阳性与 CAA/缺血性 CSVD 负荷及认知下降的关系。结果显示 66.2% 患者 Aβ 阳性,Aβ 阳性与更多脑叶微出血、皮层表面铁沉积、ε4 携带及多个认知域更快下降相关。
要点
- 记忆门诊 probable CAA 患者中 66.2% 为 Aβ PET 阳性。
- Aβ 阳性 CAA 患者脑叶微出血更多、皮层表面铁沉积更常见。
- Aβ 阳性与语言、视空间及言语记忆等认知域更快下降相关。
核心结论
- 在记忆门诊的 probable CAA 患者中,相当比例为 Aβ PET 阴性,Aβ 阳性与不同的 CSVD 生物标志物表达模式及更差认知轨迹相关。
研究设计与样本
- 研究纳入 65 例符合改良 Boston 标准的 probable CAA 患者,均接受淀粉样蛋白 PET、MRI、APOE 基因分型及神经心理学测试。
主要发现
- 65 例 CAA 患者中 43 例(66.2%)Aβ PET 阳性。
- Aβ 阳性患者脑叶微出血中位数 9(四分位距 2-41),Aβ 阴性患者为 3(2-8),P=0.045。
- Aβ 阳性患者皮层表面铁沉积频率 34.9%,Aβ 阴性患者为 9.1%,P=0.025。
- Aβ 阴性患者腔隙灶中位数 1(0-2),Aβ 阳性患者为 0(0-1),P=0.029;重度白质高信号频率在 Aβ 阴性患者为 45.5%,Aβ 阳性患者为 20.9%,P=0.040。
- Aβ 阳性患者 ε4 携带频率 57.1%,Aβ 阴性患者为 18.2%,P=0.003。
关键数值与推荐
- Aβ 阳性与语言(P<0.001)、视空间功能(P<0.001)及言语记忆(P<0.001)等认知域更快下降相关(线性混合效应模型)。
临床怎么用
- 对 probable CAA 患者评估 Aβ PET 有助于识别 CSVD 生物标志物模式不同及认知下降更快的亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated the frequency and clinical significance of amyloid β (Aβ) positivity on PET in patients with cerebral amyloid angiopathy (CAA). METHODS: We recruited 65 patients who met the modified Boston criteria for probable CAA. All underwent amyloid PET, MRI, APOE genotyping and neuropsychological testing, and we obtained information on MRI markers of CAA and ischemic cerebral small-vessel disease (CSVD). We investigated the CAA/ischemic CSVD burden and APOE genotypes in relation to Aβ positivity and investigated the effect of Aβ positivity on longitudinal cognitive decline. RESULTS: Among the 65 CAA patients, 43 (66.2%) showed Aβ PET positivity (Aβ+). Patients with Aβ+ CAA had more lobar microbleeds (median 9, interquartile range 2-41, vs. 3, 2-8; P = 0.045) and a higher frequency of cortical superficial siderosis (34.9% vs. 9.1%; P = 0.025), while patients with Aβ- CAA had more lacunes (1, 0-2, vs. 0, 0-1; P = 0.029) and a higher frequency of severe white matter hyperintensities (45.5% vs. 20.9%; P = 0.040). The frequency of ε4 carriers was higher in Aβ+ patients (57.1%) than in Aβ- patients (18.2%; P = 0.003), while the frequency of ε2 carriers did not differ between the two groups. Finally, Aβ positivity was associated with faster decline in multiple cognitive domains including language (P < 0.001), visuospatial function (P < 0.001), and verbal memory (P < 0.001) in linear mixed effects models. CONCLUSION: Our findings suggest that a significant proportion of patients with probable CAA in a memory clinic are Aβ- on PET. Aβ positivity in CAA patients is associated with a distinct pattern of CSVD biomarker expression, and a worse cognitive trajectory. Aβ positivity has clinical relevance in CAA and might represent either advanced CAA or additional Alzheimer's disease neuropathological changes.
引用
- Jang H, Jang YK, Kim HJ, et al. Clinical significance of amyloid β positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging. 2019. PMID: 30937462. doi:10.1007/s00259-019-04314-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。